New antiretrovirals and the Revised European HIV/AIDS classification

1. Castro, K.G., Ward, J.W., Slutsker, L. et al. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR. 1992 / 41(RR-17). Dostupné na: http://www. cdc.gov/mmwr/preview/mmwrhtml/00018871.htm

2. DeJesus, E., Berger, D., Markowitz, M. et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 2006, 43(1), p. 1-5.

3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. January 29, 2008. Dostupné na: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf

4. Grinsztejn, B., Nguyen, B-Y., Katlama, C. et al. Potent Antiretrovirall Effect of MK-0518, a Novell HIIV-1 Integrase Inhibitor, in Patients with Triplle-class Resistant Virus. Abstracts. ICAAC 2006. Abstract book. ABS # H-1670b.

5. Grinsztejn, B., Nguyen, B-Y., Katlama, C. et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369, p. 1261-1269.

6. Gulick, R.M., Su, Z., Flexner, C. et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 2007, 196(2), p. 304-312.

7. Hazuda, D.J., Felock, P., Witmer, M. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287(5453), p. 646-650.

8. Lazzarin, A., Campbell, T., Clotet, B. et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370(9581), p. 39-48.

9. MacArthur, R.D., Novak, R.M. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 2008, 47(2), p. 236-241.

10. Madruga, J.V., Cahn, P., Grinsztejn, B. et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370(9581), p. 29-38.

11. Markowitz, M., Morales-Ramirez, J.O., Nguyen, B-Y. et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 2006, 43(5), p. 509-515.

12. Moore, J.P., Kitchen, S.G., Pugach, P., Zack. J.A. The CCR5 and CXCR4 coreceptors—central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 2004, 20(1), p. 111-126.

13. Whitcomb, J.M., Huang, W., Fransen, S. et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 2007, 51(2), p. 566-575.

14. WHO Regional Office for Europe. Annex 2. Revised WHO clinical staging of HIV/AIDS for adults and adolescents. In: Eramova I, Matic S, Munz M.: HIV/AIDS teatment and the clinical protocols for the WHO European region. World Health Organization, 2007, p. 18-64.